FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.
Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression,
What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a standalone treatment for major depressive disorder or MDD.
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had
FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to the company, approval was supported by a pivotal placebo-controlled study in which Spravato demonstrated rapid and superior improvements in depressive symptoms as early as 24 hours,
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as standalone treatment
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult population.
BioSpace5d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
FiercePharma6d
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapy
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...